Home » Authors » Jim Shrine

Articles by Jim Shrine

NeurogesX Presents Positive Data From Trial Of Pain Patch

Nov. 1, 2011

No Abstract

NewCo News: Aileron Raises $7M For Work On Peptide Technology Platform

Nov. 1, 2011

No Abstract

KineMed Applying Translation Technologies In Deal With Bayer

Nov. 1, 2011

No Abstract

Renovis Cuts Staff As Focus Moves To Preclinical Programs

Nov. 1, 2011

No Abstract

Santhera Starts Phase III Trial In Friedreich's Ataxia Patients

Oct. 1, 2007

Santhera Starts Phase III Trial In Friedreich's Ataxia Patients

Oct. 1, 2007

NPS, Nycomed Enter Potential $185M Deal Covering Gattex

Sep. 27, 2007

NPS, Nycomed Enter Potential $185M Deal Covering Gattex

Sep. 27, 2007

Sonus Crashes On Failed Pivotal Trial Of Tocosol Paclitaxel Drug

Sep. 25, 2007

Sonus Crashes On Failed Pivotal Trial Of Tocosol Paclitaxel Drug

Sep. 25, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...